Apixaban (Eliquis)

DRUG3 trials

Sponsors

Bayer, Oslo University Hospital

Conditions

AnticoagulantsAtrial FibrillationNon-valvular Atrial FibrillationVenous Malformation, Low Flow

Phase 2

A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation

Not yet recruitingNCT06729034

Oslo University HospitalAnticoagulants, Venous Malformation, Low Flow

Start: 2025-02-01End: 2031-12-31Target: 20Updated: 2024-12-11

Unknown Phase

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

TerminatedNCT03715725

BayerNon-valvular Atrial Fibrillation

Start: 2018-10-31End: 2020-01-20Updated: 2020-12-10

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

CompletedNCT03847181

BayerAtrial Fibrillation

Start: 2019-02-28End: 2020-10-31Updated: 2021-10-28